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Abstract
Background: The Roche CARDIAC proBNP point-of-
care (POC) test is the first test intended for the quan-
titative determination of N-terminal pro-brain
natriuretic peptide (NT-proBNP) in whole blood as an
aid in the diagnosis of suspected congestive heart fail-
ure, in the monitoring of patients with compensated
left-ventricular dysfunction and in the risk stratifica-
tion of patients with acute coronary syndromes.
Methods: A multicentre evaluation was carried out to
assess the analytical performance of the POC NT-
proBNP test at seven different sites.
Results: The majority of all coefficients of variation
(CVs) obtained for within-series imprecision using
native blood samples was below 10% for both 52
samples measured ten times and for 674 samples
measured in duplicate. Using quality control material,
the majority of CV values for day-to-day imprecision
were below 14% for the low control level and below
13% for the high control level. In method comparisons
for four lots of the POC NT-proBNP test with the lab-
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oratory reference method (Elecsys proBNP), the slope
ranged from 0.93 to 1.10 and the intercept ranged
from 1.8 to 6.9. The bias found between venous and
arterial blood with the POC NT-proBNP method was
F5%. All four lots of the POC NT-proBNP test inves-
tigated showed excellent agreement, with mean dif-
ferences of between y5% and q4%. No significant
interference was observed with lipaemic blood (tri-
glyceride concentrations up to 6.3 mmol/L), icteric
blood (bilirubin concentrations up to 582 mmol/L),
haemolytic blood (haemoglobin concentrations up to
62 mg/L), biotin (up to 10 mg/L), rheumatoid factor (up
to 42 IU/mL), or with 50 out of 52 standard or cardio-
logical drugs in therapeutic concentrations. With biso-
prolol and BNP, somewhat higher bias in the low
NT-proBNP concentration range (-175 ng/L) was
found. Haematocrit values between 28% and 58% had
no influence on the test result. Interference may be
caused by human anti-mouse antibodies (HAMA)
types 1 and 2. No significant influence on the results
with POC NT-proBNP was found using volumes of
140–165 mL. High NT-proBNP concentrations above
the measuring range of the POC NT-proBNP test did
not lead to false low results due to a potential high-
dose hook effect.
Conclusions: The POC NT-proBNP test showed good
analytical performance and excellent agreement with
the laboratory method. The POC NT-proBNP assay is
therefore suitable in the POC setting.
Clin Chem Lab Med 2006;44:1269–77.
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Introduction
Chronic heart failure (CHF) is the only cardiovascular
disease that is still characterised by increasing inci-
dence and prevalence (1, 2). Therefore, accurate diag-
nosis and adequate management of such patients
have an important impact on healthcare systems.
Consequently, the guidelines of the European Soci-
ety of Cardiology recommend analysis of brain natriu-
retic peptide (BNP) or N-terminal proBNP (NT-
proBNP), in combination with assessment of symp-
toms and clinical findings, electrocardiogram, chest
X-ray and Doppler-echocardiography, when evaluat-
ing patients with suspected heart failure (3, 4).
Numerous retrospective and prospective clinical stud-
ies have demonstrated that a wide range of clinical
applications related to heart failure (and acute coro-
nary syndromes), including diagnosis, monitoring
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Figure 1 Within-series imprecision of POC NT-proBNP
using patient samples (ns10 replicates). j lot 226382-30; 
lot 226383-30; m lot 226384-30; d lot 226396-30. CV, coeffi-
cient of variation
Table 1 Within-series imprecision of the POC NT-proBNP method using patient blood samples or controls with four lots of
POC NT-proBNP on two instruments.
Blood samples Controls
Concentration range, ng/L Low level High level
60–125 125–3000 60–3000
188 ng/La 1188 ng/La
9.6 7.8 8.1 7.9 7.4
ns99 duplicates ns575 duplicates ns674 duplicates ns317 duplicates ns313 duplicates
Mean coefficients of variation (CV, %) of the duplicates are shown. a Mean value.
and prognosis, may benefit from the determination of
these peptides.
NT-proBNP testing has been shown to be useful in
ruling out acute heart failure in the emergency depart-
ment (5–8) and to improve the diagnostic accuracy of
heart failure in the primary care setting (9, 10). Plasma
NT-proBNP is a powerful predictor of in-hospital and
long-term mortality of patients with severe heart fail-
ure (11–16). Furthermore, a small pilot study showed
that adjustment of heart failure therapy guided by
serial measurements of NT-proBNP can improve out-
come compared to intensive clinically guided treat-
ment (17).
The physiologically active hormone BNP and the
inactive NT-proBNP are released from the myocardi-
um as a response to myocardial stretch. Both are
cleavage products of the precursor peptide proBNP.
NT-proBNP was shown to have a similar or even bet-
ter correlation to left ventricular dysfunction as BNP
(18). In addition, NT-proBNP is stable for up to at least
72 h after blood sampling, and has a longer half-life
and consequently higher plasma levels compared to
BNP (19–21).
According to the guidelines of the National Acade-
my of Clinical Biochemistry on biomarkers of acute
coronary syndrome and heart failure, BNP or NT-
proBNP testing should be performed on a 24-h basis,
and results should be provided with a turnaround
time from blood collection within 60 min. Point-of-
care testing is therefore favoured in cases for which
the central laboratory cannot provide test results con-
tinuously within this time interval (22).
The cost-effectiveness of point-of-care testing has
been reported with respect to length of stay in the
coronary care unit (23), time to discharge from the
emergency department (ED) (23) or from the hospital
(24), and total treatment costs in the ED (24).
The Roche CARDIAC proBNP test (Roche Diagnos-
tics GmbH, Mannheim, Germany) is the first point-of-
care (POC) test for the determination of NT-proBNP
and the fourth test developed for the Roche cardiac
reader system. The test uses one monoclonal and one
polyclonal antibody for the quantitative measurement
of NT-proBNP in heparinised whole blood. The test
principle, using a biotinylated and a gold-labelled
antibody and sandwich-type detection of the analyte,
is comparable to the other tests of the Roche cardiac
reader system, Roche cardiac T Quantitative, Roche
CARDIAC M and Roche CARDIAC D-Dimer (25–27).
The measurement range of the test is between 60
and 3000 ng/L. It is calibrated against the Elecsys
proBNP comparison method using heparinised blood
with the POC NT-proBNP test and heparinised plasma
with the laboratory NT-proBNP test. The reaction time
is approximately 12 min and the sample volume is
150 mL.
We present here the results of an analytical multi-
centre evaluation of the POC NT-proBNP test.
Materials and methods
Analytical methods
POC NT-proBNP measurements were performed using the
Roche CARDIAC proBNP test with heparinised blood or qual-
ity control material (Roche CARDIAC Control proBNP Level
Low and High; Roche Diagnostics). The instrument used was
the Roche cardiac reader (Roche Diagnostics). Comparisons
were made using the NT-proBNP assay on the Elecsys family
of analysers (Roche Diagnostics) with heparinised plasma
(20, 28, 29).
Imprecision studies
Within-series imprecision for blood samples and controls
Imprecision was determined for native heparinised blood
samples at four centres using 10 replicates of 52 samples.
The imprecision was further determined at seven centres
using 674 duplicate measurements for native heparinised
blood samples and 317 and 312 duplicate measurements of
the controls, with each replicate on a different instrument.
All coefficients of variation (CVs) were calculated using the
mean value (MV) and standard deviation (SD) for the dupli-
cate or ten-fold series: CV, %sSD/MV=100.
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Figure 2 Comparison of duplicate measurements with two
instruments: POC NT-proBNP, Reader 1, all lots, heparinised
venous blood (HVB) vs. POC NT-proBNP, Reader 2, all lots,
heparinised venous blood (HVB). ys1.02xq1.6 (Bablok-
Passing regression); rs0.98; ns874. MV, mean value.
(A) Regression plot and (B) Bland-Altman plot.
Figure 3 Day-to-day imprecision of POC NT-proBNP using
system controls (ns11–39 days): j lot 226382-30;  lot
226383-30; m lot 226384-30; d lot 226396-30. CV, coefficient
of variation.
Figure 4 Method comparison with the laboratory method:
POC NT-proBNP, lot 226382-30, heparinised venous blood
(HVB) vs. laboratory NT-proBNP method, heparinised
venous plasma (HVP). ys1.01xq3.9 (Bablok-Passing regres-
sion); rs0.95; ns279. (A) Regression plot and (B) Bland-Alt-
man plot.
Day-to-day imprecision for controls Day-to-day impreci-
sion data were obtained from daily quality control measure-
ments for 11–39 days (one sample/day per instrument). Only
evaluation centres with a 10-day measurement period or
longer were considered for the data analysis. Five centres
fulfilled this criterion; two did not and were disregarded. The
controls were freshly reconstituted each day and were meas-
ured on each instrument.
Method comparisons with the laboratory
NT-proBNP method
Comparisons between the POC and laboratory NT-proBNP
methods were carried out at seven centres. A total of 420
samples from patients with suspected heart failure and 168
samples from healthy volunteers were studied. Informed
consent according to the Helsinki declaration was obtained
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Table 2 Method comparisons for POC NT-proBNP (heparinised blood) vs. laboratory NT-proBNP (heparinised plasma).
x y n Median bias, % Mean bias, % r a b
Lab NT-proBNP POC NT-proBNP, lot 226382 279 1.6 3.3 0.95 3.9 1.01
Lab NT-proBNP POC NT-proBNP, lot 226383 119 –4.7 1.7 0.94 6.9 0.93
Lab NT-proBNP POC NT-proBNP, lot 226384 83 0.6 1.3 0.98 1.8 0.99
Lab NT-proBNP POC NT-proBNP, lot 226396 74 11.5 7.8 0.95 5.6 1.10
Regression was calculated according to Passing and Bablok: ysaqb=x, with r the correlation coefficient.
Figure 5 Comparison of sample materials: POC NT-proBNP,
heparinised venous blood (HVB) vs. POC NT-proBNP, hepar-
inised arterial blood (HAB). ys1.05x–12.8 (Bablok-Passing
regression); rs0.96; ns62. (A) Regression plot and
(B) Bland-Altman plot.
from all patients and volunteers. Venous heparinised blood
samples were collected and measured with the POC NT-
proBNP test within 4 h. Samples were then centrifuged and
the resulting plasma samples were deep-frozen and later
analysed using the laboratory NT-proBNP test in one core
laboratory.
Comparison of sample materials
At two centres the performance of the POC NT-proBNP
method using arterial heparinised blood was compared with
that for venous heparinised blood. A total of 62 venous and
arterial heparinised blood samples were collected in parallel
from patients undergoing cardiac catheterisation and were
assayed using the POC NT-proBNP method.
Lot-to-lot comparisons
To verify the reproducibility of the calibration, four lots of
the POC NT-proBNP test were investigated using fresh hepa-
rinised venous blood collected from 420 patients with sus-
pected heart failure and from 168 healthy volunteers.
Daily quality control
Quality control of the POC NT-proBNP test comprised daily
determination of the manufacturer’s controls at each centre.
Quality control of the laboratory NT-proBNP test was per-
formed with the respective package controls during each
run.
Interference testing
For interference testing, heparinised blood or plasma was
spiked with biotin, bilirubin, rheumatoid factor, or drugs (for
concentrations see Table 4; for concentrations of the drugs
see Table 5) and with NT-proBNP pool serum. The NT-
proBNP pool serum was obtained from remainders of ano-
nymised samples from dialysis patients.
To determine the potential interference of haemoglobin,
patient blood samples were haemolysed by passing them
multiple times through a syringe and needle. The resulting
free haemoglobin concentrations in plasma were measured
photometrically according to Fairbanks et al. (30). The recov-
ery of spiked NT-proBNP concentrations before and after the
haemolysis procedure was determined.
The POC NT-proBNP test uses the monoclonal antibody
MAB-CK MM-M 33-IgG (MAB 33, Roche Diagnostics) as a
blocking agent to avoid interference with human anti-mouse
antibodies (HAMA). The influence of HAMA on POC NT-
proBNP was tested by adding MAB 33 and NT-proBNP to
commercial HAMA type 1 and type 2 samples (Roche Diag-
nostics). Interference can be excluded if the recovery of NT-
proBNP in the sample does not change with increasing
concentrations of the HAMA-blocking agent MAB 33.
To determine the influence of haematocrit and triglycer-
ides, method comparisons using the samples collected from
patients with suspected congestive heart failure and from
healthy volunteers were carried out.
Influence of sample volume
The sample volume dependence was investigated with vol-
umes between 135 and 165 mL. Heparinised blood samples
from healthy volunteers spiked with NT-proBNP were used
in these experiments.
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Figure 6 Lot-to-lot comparison with POC NT-proBNP. Lot
226382-30, heparinised venous blood (HVB) vs. lot 226383-
30, heparinised venous blood. ys1.00xq2.6 (Bablok-Passing
regression); rs0.97; ns125. (A) Regression plot and
(B) Bland-Altman plot.
Table 3 Lot-to-lot comparison for the POC NT-proBNP method.
x y n Median bias, % Mean bias, % r a b
POC NT-proBNP, lot 226382 POC NT-proBNP, lot 226383 125 1.2 4.0 0.97 2.6 1.00
POC NT-proBNP, lot 226382 POC NT-proBNP, lot 226384 88 –1.7 –1.3 0.99 8.7 0.95
POC NT-proBNP, lot 226382 POC NT-proBNP, lot 226396 122 –2.6 –1.9 0.98 11.2 0.95
Regression was calculated according to Passing and Bablok: ysaqb=x, with r the correlation coefficient.
High-dose hook effect
Immunoassays may yield false-negative results for samples
containing very high analyte concentrations. This phenom-
enon is called the high-dose hook effect and is caused by
saturation of all antibody binding sites with antigen, pre-
venting formation of the expected sandwich complex. In
investigations into the potential high-dose hook effect, hepa-
rinised blood samples from healthy donors were spiked with
NT-proBNP up to a concentration of 35,000 ng/L.
Results and discussion
Within-series imprecision for blood samples and
controls
The majority of within-series CVs for 52 heparinised
blood samples resulting from ten-fold measurements
in the imprecision study (Figure 1), as well as the
majority of within-series CVs for heparinised blood
samples resulting from the 674 duplicate measure-
ments in the method comparison, were below 10%
(Table 1). A comparison of all 674 duplicate measure-
ments between the two instruments and a Bland-Alt-
man plot of the differences is shown in Figure 2.
The mean CVs for 317 or 313 duplicate measure-
ments during daily quality control were 8% and 7%
for the low and high POC NT-proBNP control levels,
respectively (Table 1).
Day-to-day imprecision and recovery for controls
The CVs for day-to-day imprecision for the majority
of samples were below 14% and 13% for the low and
high POC NT-proBNP control levels, respectively (Fig-
ure 3).
For all 1276 measurements using the liquid con-
trols, 100% were recovered within the target range
given by the manufacturer.
Method comparisons with the laboratory
NT-proBNP test
All lots of POC NT-proBNP showed very good agree-
ment in method comparisons with the laboratory NT-
proBNP test. The median bias compared to the
laboratory NT-proBNP method was between y5%
and q12% for different lots of POC NT-proBNP. The
slope for method comparison of POC NT-proBNP vs.
laboratory NT-proBNP ranged between 0.93 and 1.10,
and the intercept ranged between 1.8 and 6.9. The
correlations in these comparisons were G0.94 (Figure
4, Table 2).
Comparison of sample materials
There was good overall agreement between venous
and arterial blood in comparisons using two lots of
POC NT-proBNP. The bias found was F5% (Figure 5).
This difference was similar to that found for the lot-
to-lot comparisons (see below).
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Figure 7 Influence of free plasma haemoglobin on results
with POC NT-proBNP. The percentage relative recovery after
haemolysis compared to the reference before haemolysis is
shown.
Table 5 Interference of haemotocrit with the POC NT-
proBNP method, reported as the relative recovery of NT-
proBNP concentrations (measured using the laboratory
NT-proBNP method) for the POC NT-proBNP method.
Haematocrit, % Median recovery, % n
28–34 101 38
35–44 108 289
45–58 111 43
Table 6 Interference of triglycerides with the POC NT-
proBNP method, reported as the relative recovery of NT-
proBNP concentrations (measured using the laboratory
NT-proBNP method) for the POC NT-proBNP method.
Triglyceride concentration,
mmol/L
Median recovery,
%
n
0–1.9 106 153
2.0–3.9 107 60
4.0–6.3 89 14
Table 4 Interference of biotin, bilirubin and rheumatoid fac-
tor with the POC NT-proBNP method.
Interferent NT-proBNP concentration
range, ng/L
0–88 89–222 659–1557
Biotin, mg/L
0, reference 100 100 100
3 -LLMR 90 93
10 -LLMR 92 99
20 -LLMR 84 101
30 -LLMR 83 85
Bilirubin, mmol/L
0, reference 100 100 100
342 96 99 101
582 93 96 102
Rheumatoid factor, IU/mL
0, reference 100 100 100
16 -LLMR 89 90
42 -LLMR 97 96
52 -LLMR 93 78
181 -LLMR 66 73
The percentage relative recovery compared to the reference
is reported. -LLMR, below the lower limit of the measuring
range.
Lot-to-lot comparisons
In comparisons of different lots of POC NT-proBNP,
all lots showed excellent agreement, demonstrating
the reproducibility of the calibration. The differences
between the lots ranged from y5% to q4% (Figure 6,
Table 3).
Interference testing
The influence of haemoglobin on the POC NT-pro-
BNP test result was within "7% up to a haemoglobin
concentration of 35 mg/L and within "14% up to
62 mg/L. At higher concentrations (62–110 mg/L), a
lower recovery was observed in all samples (ns5),
one of which deviated by )15% (Figure 7).
In investigations with biotin of up to 10 mg/L, bili-
rubin up to 582 mmol/L and rheumatoid factor up to
42 IU/mL (Table 4) no analytical interference was
detected, i.e., all deviations from expected values
were F15%.
The recovery of laboratory NT-proBNP concentra-
tions according to the POC NT-proBNP test was
between 101% and 111% for the haematocrit range
studied (Table 5). Moreover there was no correlation
between haematocrit and the relative POC NT-pro-
BNP/laboratory NT-proBNP method differences
(rs0.16), indicating no influence on the result by hae-
matocrit values between 28% and 58%.
There was no influence of triglycerides at up to
6.3 mmol/L, as demonstrated by recoveries from 89%
to 107% (Table 6). The correlation coefficient between
triglyceride concentration and the relative POC NT-
proBNP/lab NT-proBNP method differences was low
(rsy0.05).
The interference of drugs was tested with toxic con-
centrations of each drug and was repeated with ther-
apeutic concentrations if an influence was found. At
therapeutic concentrations, 50 out of the 52 drugs
investigated did not influence the POC NT-proBNP
result by more than "15%. With bisoprolol and BNP,
somewhat higher bias in the low NT-proBNP concen-
tration range (-175 ng/L) was found, which did not
exceed "33 ng/L in absolute terms (Table 7).
With HAMA serum type 1 and type 2, the recovery
was reduced or elevated if MAB 33 was added. Thus,
interference from HAMA type 1 and type 2 positive
sera was not completely eliminated (Table 8).
Influence of sample volume
There was a slight trend to lower recovery when low
sample volumes were applied to the test compared to
the regular volume of 150 mL, but overdosing or
underdosing by 10 mL did not affect the test result
significantly (Figure 8). Insufficient filling of the test
strip should be avoided by using a professional lab-
oratory pipette or the POC system pipette supplied by
the manufacturer.
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Table 7 Interference of drugs with the POC NT-proBNP method.
Drug NT-proBNP concentration range, ng/L
0–106 107–241 864–1519
No drug, reference 100 100 100
Acetaminophen, 200 mg/mL 85 91 93
Acetylcysteine, 150 mg/mL 101 128 118
Acetylcysteine, 30 mg/mL -LLMR 99 105
Acetylsalicylic acid, 1 mg/mL 108 110 107
Adrenaline, 0.37 mg/mL -LLMR 84 86
Adrenaline, 0.074 mg/mL -LLMR 91 97
Ampicillin, 1.0 mg/mL -LLMR 98 82
Ampicillin, 0.2 mg/mL -LLMR 106 98
Ascorbic acid, 300 mg/mL -LLMR 91 96
Bisoprolol, 10 mg/mL -LLMR 87 83
Bisoprolol, 2 mg/mL ND 117 107
BNP, 25 mg/mL -LLMR 123 113
Ca-Dobesilate, 200 mg/mL -LLMR 87 88
Captopril, 150 mg/mL 108 100 95
Carvedilol, 50 mg/mL -LLMR 94 98
Cefoxitin, 2.5 mg/mL 87 59 48
Cefoxitin, 0.5 mg/mL -LLMR 94 95
Cyclosporin, 5 mg/mL 108 101 91
Digitoxin, 0.3 mg/mL -LLMR 85 93
Digoxin, 0.5 mg/mL -LLMR 88 91
Doxycyclin, 50 mg/mL -LLMR 94 98
Enalapril maleate, 40 mg/mL -LLMR 83 91
Enalapril maleate, 8 mg/mL -LLMR 99 97
Gentamicin, 0.5 mg/mL -LLMR 85 83
Gentamicin, 0.1 mg/mL -LLMR 94 101
Glycerol trinitrate, 192 mg/mL -LLMR 91 96
Heparin, unfractionated, 5000 U/L -LLMR 93 111
Heparin, LMW, 29 mg/mL -LLMR 106 93
Ibuprofen, 500 mg/mL ND 87 89
Ibuprofen, 100 mg/mL -LLMR 88 91
Insulin, 840 mg/mL -LLMR 93 93
Intralipid, 10 mg/mL -LLMR 92 101
Levodopa, 20 mg/mL 100 100 96
Lidocaine, 100 mg/mL -LLMR 102 98
Lisinopril dehydrate, 40 mg/mL ND 107 85
Lisinopril dehydrate, 8 mg/mL -LLMR 87 100
Lovastatin, 80 mg/mL -LLMR 81 83
Lovastatin, 16 mg/mL ND ND 100
Methyldopa, 20 mg/mL 84 92 101
Methylprednisolone, 80 mg/mL -LLMR 102 94
Metoprolol, 15 mg/mL -LLMR 92 88
Metronidazole, 200 mg/mL 102 92 91
Molsidomine, 24 mg/mL -LLMR 90 108
Nicardipine, 90 mg/mL -LLMR 96 95
Nifedipine, 60 mg/mL -LLMR 92 92
Phenprocoumon, 6 mg/mL -LLMR 90 92
Phenylbutazone, 400 mg/mL 114 91 81
Phenylbutazone, 80 mg/mL 121 106 103
Pravastatin, 40 mg/mL -LLMR 90 80
Pravastatin, 8 mg/mL -LLMR 107 100
Propafenone, 900 mg/mL -LLMR -LLMR 60
Propafenone, 180 mg/mL -LLMR 91 97
Propranolol, 0.32 mg/mL 129 109 105
Propranolol, 0.064 mg/mL -LLMR 99 101
Renin, 205 mU/mL 91 102 86
Reteplase, 1.12 mg/mL 120 106 93
Rifampicin, 60 mg/mL 111 102 92
Simvastatin, 40 mg/mL ND 115 92
Simvastatin, 8 mg/mL -LLMR 89 99
Sotalol, 320 mg/mL -LLMR 106 93
Spironolactone, 400 mg/mL -LLMR 110 103
Streptokinase, 300 IE -LLMR 94 107
Theophylline, 1.0 mg/mL -LLMR 80 85
Theophylline, 0.2 mg/mL -LLMR 89 94
Tolbutamide, 3 mg/mL -LLMR 89 91
Torasemide, 200 mg/mL -LLMR 84 68
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(Table 7 continued)
Drug NT-proBNP concentration range, ng/L
0–106 107–241 864–1519
Torasemide, 40 mg/mL -LLMR 104 90
Urokinase, 34.5 U -LLMR 101 109
Verapamil, 120 mg/mL -LLMR 84 100
Verapamil, 24 mg/mL -LLMR 97 91
The percentage relative recovery compared to the reference is reported. A second, lower therapeutic concentration of a drug
was tested if an influence was found with the higher toxic concentration. -LLMR, below the lower limit of the measuring
range; ND, not determined.
Table 8 Interference of HAMA sera with the POC NT-proBNP method.
Interferent MAB 33, mg/mL NT-proBNP concentration range, ng/L
0–60 337–366
HAMA type 1 0, reference 100 100
0.1 -LLMR 105
1 -LLMR 100
10 -LLMR 86
HAMA type 2 0, reference 100 100
0.1 -LLMR 111
1 -LLMR 117
10 -LLMR 99
The percentage relative recovery after addition of HAMA-blocking agent MAB 33 compared to the reference without MAB 33
is reported. -LLMR, below the lower limit of the measuring range.
Figure 8 Influence of sample volume on POC NT-proBNP
results. NT-proBNP concentrations: j 156 ng/L; d 147 ng/L;
 131 ng/L; m 127 ng/L; h 144 ng/L; s 115 ng/L; e 186
ng/L; n 1345 ng/L. Mean recoveries of 20 replicates per vol-
ume are shown.
High-dose hook effect
High NT-proBNP concentrations above the measuring
range of the POC NT-proBNP test did not lead to false-
negative or false low results due to a potential high-
dose hook effect. With NT-proBNP concentrations
between 10,000 and 35,000 ng/L, the instrument dis-
played either ‘‘High )3000 pg/mL’’ or an error mes-
sage. If a quantitative result in this range is needed,
the measurement has to be repeated with a labora-
tory NT-proBNP method.
Conclusions
With the new POC NT-proBNP test, reliable quantita-
tive NT-proBNP results can easily be obtained within
less than 15 min. Owing to its excellent analytical con-
cordance with the laboratory NT-proBNP test, we
expect a similar diagnostic performance for this
assay. The test should therefore be well suited to its
intended use as an aid in the diagnosis of patients
suspected of having congestive heart failure, in the
monitoring of patients with compensated left-ventric-
ular dysfunction, and in the risk stratification of
patients with acute coronary syndromes.
A higher level of evidence for its clinical utility may
be obtained in clinical studies using the POC NT-
proBNP test. Hence, a prospective trial on the efficacy
of the POC NT-proBNP test in treatment guidance for
chronic heart failure patients in heart failure clinics
was designed and is currently ongoing.
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